GH — Guardant Health, Inc.

Summary of Guardant Health Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $265.2 million, up 39% year-over-year.
• Oncology Revenue: $184.4 million, a 31% increase, with approximately 74,000 tests conducted (40% growth).
• Biopharma and Data Revenue: $54.7 million, an 18% increase.
• Screening Revenue (Shield): $24.1 million from 24,000 tests.
• Gross Margin: Non-GAAP gross margin improved to 66% from 63% year-over-year.
• Adjusted EBITDA Loss: $45.5 million, an improvement from a loss of $56.2 million in Q3 2024.
• Free Cash Flow Burn: $45.8 million, improved compared to the prior year.
• Cash Position: Approximately $690 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• Oncology Growth: Continued acceleration in oncology volumes, particularly with Guardant360 Liquid, which has seen five consecutive quarters of growth.
• Screening Initiatives: Shield tests are gaining traction, with a significant increase in commercial partnerships (e.g., with Quest Diagnostics and PathGroup) to enhance access.
• Regulatory Progress: Submitted PMA application for Guardant360 Liquid to the FDA, which could streamline offerings and enhance market adoption.
• Infinity AI: Leveraging AI to enhance product development and clinical insights, with 15 Smart apps launched to date.
• Patient Impact Stories: Highlighted the effectiveness of Shield in improving patient screening compliance and outcomes.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to $965 million to $970 million, reflecting strong year-to-date performance.
• Oncology Revenue Growth: Expected to grow approximately 25% year-over-year.
• Shield Revenue Guidance: Increased to $71 million to $73 million, with anticipated test volumes of 80,000 to 82,000.
• Operating Expenses: Expected to rise to $865 million to $875 million, driven by investments in commercial infrastructure.
• Long-term Goals: Aim for cash flow breakeven by the end of 2027, with a continued focus on reducing cash burn.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Concerns regarding new entrants in the market, particularly in colorectal cancer screening, which may impact Shield's market share.
• Regulatory Uncertainty: Potential delays in obtaining ADLT status and reimbursement for Reveal, particularly in breast cancer.
• Market Penetration: Despite growth, MRD testing remains a relatively open market, with only about 10% penetration, indicating room for competition and challenges in gaining broader acceptance.
• Operational Risks: Continued reliance on Medicare and Medicare Advantage for revenue, with potential fluctuations in reimbursement rates.

5. Notable Q&A Insights

• ASP Dynamics: Management discussed the stability of Shield's average selling price (ASP) and the impact of Medicare reimbursement rates on future pricing.
• Guideline Inclusion: There is optimism regarding potential inclusion of Shield in American Cancer Society guidelines, which could enhance reimbursement opportunities.
• Growth Drivers: The growth in Guardant360 is attributed to share gains, increased testing frequency, and the introduction of new capabilities through Smart apps.
• Reveal's Future: Discussion on the potential for Reveal Ultra and its expected sensitivity improvements, with ongoing studies to support its clinical utility.
• Sales and Marketing Investments: Significant focus on expanding the sales force and marketing efforts to drive adoption of Shield and oncology products.

Overall, Guardant Health demonstrated strong financial performance in Q3 2025, with significant growth across its oncology and screening businesses, while also navigating competitive and regulatory challenges.